Drug Profile

Anti CD33/CD123 chimeric antigen receptor T cell therapy - Essen Biotech

Alternative Names: CD123/CD33 CART; EBBH-2025

Latest Information Update: 09 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Essen BioTech
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Jul 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in China (IV, Infusion) (NCT06420063)
22 May 2024 Essen Biotech plans a phase I/II trial for Acute myeloid leukemia (Second-line therapy or greater; In adults, In the elderly) in China in October 2024 (IV) (NCT06420063)
22 May 2024 Preclinical trials in Acute myeloid leukaemia in USA (IV, Infusion), prior to May 2024 (Essen Biotech website, May 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com